Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance.

ABSTRACT:

Background

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are an established treatment for patients with type 2 diabetes (T2D). Differences between GLP-1RAs in pharmacokinetics, dosing regimens and clinical effects, including cardiovascular (CV) outcomes, mean there may be benefits to switching from one to another. However, clinical guidance on switching is lacking and data from clinical trials are limited. This article provides a clinical perspective and consensus on the benefits of switching between GLP-1RAs, the triggers for switching and how best to manage this in clinical practice. Once weekly (OW) semaglutide is used as an example to illustrate how the authors might switch to a different GLP-1RA in clinical practice.

Methods

Literature was searched and perspectiv

SUBMITTER: Jain AB 

PROVIDER: S-EPMC7900946 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature